Published in Cancer Weekly, January 29th, 2002
In fact, the researchers, led by M. Fernandez, have developed several recombinant therapies incorporating the genetically engineered vectors and determined they are useful for battling tumors and increasing survival in murine models of several forms of malignancies.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.